☰

Zoltan Sarnyai

Affiliations: 
2003-2011 Pharmacology University of Cambridge, Cambridge, England, United Kingdom 
 2012- Laboratory of Psychiatric Neuroscience James Cook University 
Area:
stress and mental health, psychopharmacology
Website:
https://research.jcu.edu.au/portfolio/zoltan.sarnyai
Google:
"Zoltan Sarnyai"
Bio:

Dr Zoltán Sarnyai is a medically-trained PhD neuroscientist with an active research program in the neurobiological mechanisms of stress and psychiatric disorders, including drug addiction, schizophrenia and depression. After a postdoctoral training at Harvard Medical School he held an independent research position at the Rockefeller University, supported by two prestigious fellowships. Zoltán was involved in setting up a behavioural neuroscience focussed biotech company and later directed its research effort to develop new animal models for psychiatric disorders. Prior to establishing the Psychiatric Neuroscience Laboratory at JCU in 2012 he was a University Lecturer in Pharmacology and Fellow of Pembroke College at the University of Cambridge.

(Show more)

Mean distance: 13.63 (cluster 7)
 		SNBCP
Cross-listing: Chemistry Tree

Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor
Gabor L. Kovacs grad student University of Szeged
Nancy K. Mello post-doc 1992-1995 Harvard Medical School, Mclean Hospital
Bruce S. McEwen research scientist 1995-1999 Rockefeller

Children

Sign in to add trainee
Maximus Berger grad student 2015- JCU
Yolanda Kerlen grad student 2015- JCU
Ann Katrin Kraeuter grad student 2015- JCU
Vanessa Wong grad student 2015- JCU
Christopher A. R. Reid grad student 2020- James Cook University
Maki Kasahara grad student 2004-2008 Cambridge

Collaborators

Sign in to add collaborator
Berend Olivier collaborator 2003- Utrecht
Sabine Bahn collaborator 2009- Cambridge
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Amminger GP, Lin A, Kerr M, et al. (2021) Cannabidiol for at risk for psychosis youth: A randomized controlled trial. Early Intervention in Psychiatry
Phillips R, Kraeuter AK, McDermott B, et al. (2020) Human nail cortisol as a retrospective biomarker of chronic stress: A systematic review. Psychoneuroendocrinology. 123: 104903
Kraeuter AK, Phillips R, Sarnyai Z. (2020) The Gut Microbiome in Psychosis From Mice to Men: A Systematic Review of Preclinical and Clinical Studies. Frontiers in Psychiatry. 11: 799
Berger M, Amminger GP, McDermott R, et al. (2020) Testing the Effects of Dietary Seafood Consumption on Depressive Symptoms. Methods in Molecular Biology (Clifton, N.J.). 2138: 233-242
Kraeuter AK, Guest PC, Sarnyai Z. (2020) Protocol for the Use of the Ketogenic Diet in Preclinical and Clinical Practice. Methods in Molecular Biology (Clifton, N.J.). 2138: 83-98
Kraeuter AK, Phillips R, Sarnyai Z. (2020) Ketogenic therapy in neurodegenerative and psychiatric disorders: From mice to men. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109913
Ketheesan S, Rinaudo M, Berger M, et al. (2020) Stress, Allostatic Load and Mental Health in Indigenous Australians. Stress (Amsterdam, Netherlands). 1-26
Kraeuter AK, Mashavave T, Suvarna A, et al. (2020) Effects of beta-hydroxybutyrate administration on MK-801-induced schizophrenia-like behaviour in mice. Psychopharmacology
Kraeuter AK, Guest PC, Sarnyai Z. (2019) The Therapeutic Potential of Ketogenic Diet Throughout Life: Focus on Metabolic, Neurodevelopmental and Neurodegenerative Disorders. Advances in Experimental Medicine and Biology. 1178: 77-101
Kraeuter AK, Archambault N, van den Buuse M, et al. (2019) Ketogenic diet and olanzapine treatment alone and in combination reduce a pharmacologically-induced prepulse inhibition deficit in female mice. Schizophrenia Research
See more...